Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA CAR-T (Hebei Senlang)
- Development stage
- Unknown
- Lead developer
- Senlang Bio
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA CAR-T (Hebei Senlang) is an autologous chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), also known as TNFRSF17. Developed by Hebei Senlang Biotechnology, this cell therapy is being evaluated in exploratory clinical trials for the treatment of refractory and relapsing ulcerative colitis (UC). BCMA is highly expressed on mature B cells and plasma cells, which are thought to play a role in the autoimmune pathogenesis of UC by secreting pro-inflammatory cytokines and potentially pathogenic autoantibodies. By specifically depleting these BCMA-expressing cells, the therapy aims to reset the immune environment and achieve long-term clinical remission in patients who have failed standard treatments.
- Other names
- BCMA-targeting CAR-T cellsAutologous BCMA CAR-T
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA CAR-T (Hebei Senlang).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA CAR-T (Hebei Senlang).